OTCMKTS:GCVRZ - Wright Medical Group Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.87
+0.30 (1.20%)
1 month | 3 months | 12 months
Get New Wright Medical Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GCVRZ and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GCVRZ

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Wright Medical Group in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.87.
N/A
The current consensus among 0 investment analysts is to n/a stock in Wright Medical Group. This rating has held steady since April 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/30/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
4/28/2019JPMorgan Chase & Co.Reiterated RatingHold$81.00
i
4/28/2019UBS GroupReiterated RatingHold$79.00
i
4/28/2019The Goldman Sachs GroupReiterated RatingHold$77.00
i
(Data available from 4/22/2016 forward)
Wright Medical Group logo
Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an immunomodulatory and Lemtrada, a monoclonal antibody to treat multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia in adults and children; and Cablivi to treat acquired thrombotic thrombocytopenic purpura in adults. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for cancers; Eloxatin for colon cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil, for hematologic malignancies; and Zaltrap, for metastatic colorectal cancer. Further, it provides Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl, a sulfonylurea; Adlyxin/Lyxumia, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug for atrial fibrillation. Additionally, it offers Plavix for atherothrombotic conditions; Lovenox for the prophylaxis, venous thromboembolism, and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; Allegra for seasonal allergic rhinitis and uncomplicated hives; and Depakine for epilepsy. It also provides generic products; consumer healthcare products for allergy, cough, cold, pain, nutrition, digestion, and others; and pediatric, influenza, adult and adolescent booster, meningitis, travel, and endemic vaccines. Sanofi was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Read More

Today's Range

Now: $0.87
$0.87
$0.87

50 Day Range

MA: $0.87
$0.87
$0.87

52 Week Range

Now: $0.87
$0.34
$0.88

Volume

N/A

Average Volume

264,629 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Wright Medical Group?

The following equities research analysts have issued research reports on Wright Medical Group in the last year:
View the latest analyst ratings for GCVRZ.

What is the current price target for Wright Medical Group?

0 Wall Street analysts have set twelve-month price targets for Wright Medical Group in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Wright Medical Group in the next year.
View the latest price targets for GCVRZ.

What is the current consensus analyst rating for Wright Medical Group?

Wright Medical Group currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for GCVRZ.

How do I contact Wright Medical Group's investor relations team?

The company's listed phone number is 33 1 53 77 40 00. The official website for Wright Medical Group is www.sanofi.com.